IVST - Innovest Global, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1600
0.0000 (0.00%)
As of 3:45PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1600
Open0.1600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1600 - 0.1600
52 Week Range0.0500 - 0.3900
Volume2,984
Avg. Volume9,552
Market Cap25.536M
Beta (5Y Monthly)-1.70
PE Ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Innovest Global Summarizes Operational and Capital Markets Approach During COVID-19

      CLEVELAND, OH / ACCESSWIRE / March 23, 2020 / Innovest Global Inc. (IVST), a diversified industrials company with a pending spinout of its biotechnology holdings, today provided an update on business operations in light of the recent COVID-19 pandemic. In 2017, just three years ago, Innovest was founded with the mindset to turn-around a distressed public company into a scalable industrials company. Innovest's goal was to enhance shareholder value by acquiring companies on favorable terms and achieving organic growth.

    • ACCESSWIRE

      Innovest Global Acquires 100% of StemVax Therapeutics

      CLEVELAND, OH / ACCESSWIRE / March 3, 2020 / Innovest Global Inc. (OTC PINK:IVST), a diversified industrials company, has completed the acquisition of 100% interest in StemVax Therapeutics, a biotechnology company developing novel therapies for brain tumor patients. Since acquiring a 20% interest in StemVax in July 2018, Innovest has developed its biotech division to rapidly accelerate research and development to successfully bring safe and efficacious novel immunotherapeutics to market.

    • ACCESSWIRE

      Innovest Global to Present at the LD Micro Virtual Investor Conference on March 4, 2020 at 3:40 p.m. ET

      Management to Showcase New Investor Presentation & Business Model During Online Event CLEVELAND, OH / ACCESSWIRE / February 25, 2020 / Innovest Global, Inc. (OTC: IVST ), a diversified industrials company ...

    • ACCESSWIRE

      Innovest Global Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

      CLEVELAND, OH / ACCESSWIRE / February 12, 2020 / Innovest Global Inc. (OTCPINK:IVST), a diversified industrials company, has engaged international investor relations specialists MZ Group (MZ) to lead a ...